Our findings suggest that identification of agents which increase hepatic TOMM40 expression, and in doing so, maintain mitochondrial function and MERCs, could provide new therapeutic opportunities for MASLD, as well as other conditions such as Alzheimer’s disease in which mitochondrial pathology plays a role. This evidence concerns the gene TOMM40 and Alzheimer disease.